Published in:
01-09-2016 | Original Article—Alimentary Tract
Incidence of, phenotypes of and survival from small bowel cancer in Denmark, 1994–2010: a population-based study
Authors:
Rasmus Dahlin Bojesen, Mikael Andersson, Lene Buhl Riis, Ole Haagen Nielsen, Tine Jess
Published in:
Journal of Gastroenterology
|
Issue 9/2016
Login to get access
Abstract
Background
Small bowel cancer (SBC) is a rare and highly heterogeneous disease in respect to both anatomical distribution and histological morphology. We aimed to conduct a Danish nationwide population-based cohort study of the incidence of, phenotypes of, stage of, synchronous/metachronous cancer occurrence of and survival from SBC during 1994–2010.
Methods
The study population included all individuals aged 16 years or older living in Denmark during 1994–2010 (n = 7,070,142). Patients with SBC were identified through the Danish Cancer Registry. Incidence rates were calculated overall and according to the anatomical origin and morphological subtype. Patients were followed up from the date of cancer diagnosis to the date of emigration, death or the end of the study (31 December 2010).
Results
SBC was diagnosed in 1088 patients during 1994–2010. The total annual incidence of SBC was 1.10 per 100,000 [95 % confidence interval (CI) 1.04 to 1.17 per 100,000], with an annual percentage change of 1.9 % (95 % CI 0.6–3.1 %, p = 0.003) during the observation period. This increase was mainly explained by an increase in the occurrence of duodenal adenocarcinomas, with an annual percentage change of 7.5 % (95 % CI 4.9–10.2 %, p < 0.001). Further, 29 % of all SBC patients had metastatic cancer at the time of diagnosis and 32 % had one or more synchronous/metachronous cancers. All morphological subtypes were associated with poor 5-year prognoses, in particular duodenal adenocarcinomas, with a 5-year survival rate of only 16 % (95 % CI 12–22 %).
Conclusions
The incidence of SBC has increased in recent decades, mainly because of a large increase in the incidence of duodenal adenocarcinomas, which are also associated with the poorest prognosis.